Switzerland
· Delayed Price · Currency is CHF PolyPeptide Group AG Company Description
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India.
It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies.
The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications.
It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland.
PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
| Country | Switzerland |
| Founded | 1952 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,277 |
| CEO | Juan Gonzalez |
Contact Details
Address: Neuhofstrasse 24 Baar, 6340 Switzerland | |
| Phone | 41 435 020 580 |
| Website | polypeptide.com |
Stock Details
| Ticker Symbol | PPGN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | CH1110760852 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Juan Jose Gonzalez | Chief Executive Officer |
| Marc Augustin | Chief Financial Officer |
| Jens Fricke | Director of Global Operations |
| Rene Vestergaard | Director of Corporate Finance |
| Olivier Ludemann-Hombourger | Director Global Innovation and Technology |
| Christina Del Vecchio | General Counsel and Corporate Secretary |
| Monika Casanova | Chief Human Resources Officer |
| Christophe Chevalier | Head of Technical Department - Braine |
| Krister Svard | Chief Information Security Officer and Global IT Services VC |
| Rebecca Weil | Head of Internal Audit |